Mesenchymal stem cells versus mesenchymal stem cells combined with cord blood for engraftment failure after autologous hematopoietic stem cell transplantation: A pilot prospective, open-label, randomized trial

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 2, 2014, Pages 236-242

  Xiong, Yi Ying ^a   Fan, Qian ^a   Huang, Fen ^a   Zhang, Yu ^a   Wang, Yu ^b   Chen, Xiao Yong ^c   Fan, Zhi Ping ^a   Zhou, Hong Sheng ^a   Xiao, Yang ^d   Xu, Xiao Jun ^c   Dai, Min ^a   Xu, Na ^a   Sun, Jing ^a   Xiang, Peng ^c   Huang, Xiao Jun ^b   Liu, Qi Fa ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

Autologous hematopoietic stem cell transplantation; Cord blood; Engraftment failure; Mesenchymal stem cells

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FOSCARNET; GLOBULIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; GRAFT FAILURE; HEPATITIS B VIRUS; HUMAN; LEUKEMIA; LEUKOCYTE COUNT; MALE; MEDICAL HISTORY; MESENCHYMAL STEM CELL; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; OPEN STUDY; OVARY CANCER; OVERALL SURVIVAL; PILOT STUDY; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SAFETY; STEM CELL MOBILIZATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION; YOUNG ADULT;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CORD BLOOD; ENGRAFTMENT FAILURE; MESENCHYMAL STEM CELLS;

ADOLESCENT; ADULT; CHIMERISM; FEMALE; FETAL BLOOD; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84893145125     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.002     Document Type: Article

References (46)

1. Rossi A., Cortelazzo S., Bellavita P., et al. Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma. Br J Haematol 1997, 96:620-626.
2. Chen J., Gu L.J., Tang J.Y., et al. Treatment of advanced malignant solid tumors in children with autologous hematopoietic stem cell transplantation. Chin J Pediatr 2004, 42:924-927.
3. Copelan E.A. Hematopoietic stem-cell transplantation. NEngl J Med 2006, 354:1813-1826.
4. Devetten M., Armitage J.O. Hematopoietic cell transplantation: progress and obstacles. Ann Oncol 2007, 18:1450-1456.
5. Burnett A.K., Goldstone A.H., Stevens R.M., et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 1988, 351:700-708.
6. Pottinger B., Walker M., Campbell M., et al. The storage and re-infusion of autologous blood and BM as back-up following failed primary hematopoietic stem-cell transplantation: a survey of European practice. Cytotherapy 2002, 4:127-136.
7. Hornedo J., Sola C., Solano C., et al. The role of granulocyte colony-stimulating factor (G-CSF) in the posttransplant period. Bone Marrow Transplant 2002, 29:737-743.
8. Freytes C.O., Loberiza F.R., Rizzo J.D., et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004, 104:3797-3803.
9. Baron F., Frere P., Fillet G., Beguin Y. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. Clin Cancer Res 2003, 9:5566-5572.
10. Richard S., Schuster M.W. Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep 2002, 1:103-109.
11. Bernardo M.E., Cometa A.M., Locatelli F. Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation?. Bone Marrow Transplant 2012, 47:323-329.
12. Dazzi F., Ramasamy R., Glennie S., et al. The role of mesenchymal stem cells in haemopoiesis. Blood Rev 2006, 20:161-171.
13. Prockop D.J., Oh J.Y. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012, 20:14-20.
14. Weng J.Y., Du X., Geng S.X., et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010, 45:1732-1740.
15. Ball L.M., Bernardo M.E., Roelofs H., et al. Cotransplantation of exvivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110:2764-2767.
16. Meuleman N., Tondreau T., Ahmad I., et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells Dev 2009, 18:1247-1252.
17. Sanchez-Guijo F.M., Lopez-Villar O., Lopez-Anglada L., et al. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation. Transfusion 2012, 52:1086-1091.
18. Koc O.N., Gerson S.L., Cooper B.W., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. JClin Oncol 2000, 18:307-316.
19. Liu K., Chen Y., Zeng Y., et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study. Stem Cells Dev 2011, 20:1679-1685.
20. Muller I., Kordowich S., Holzwarth C., et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008, 40:25-32.
21. Liu X., Wu M., Peng Y., et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant 2013, 10.3727/096368912X661339.
22. Durie B.G., Harousseau J.L., Miguel J.B., et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
23. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. JClin Oncol 1999, 17:1244-1253.
24. Liu Q.F., Fan Z.P., Zhang Y., et al. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant 2009, 15:1376-1385.
25. Liu Q., Xuan L., Liu H., et al. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Am J Hematol 2013, 10.1002/ajh.23452.
26. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
27. Schulz K.F., Altman D.G., Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340:698-702. CONSORT Group.
28. Bolwellb B., Goormastic M., Andresen S., et al. Variables associated with the platelet count 6 weeks after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998, 22:547-551.
29. Bernstein S.H., Nademanee A.P., Vose J.M., et al. Amulticenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998, 91:3509-3517.
30. + progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant 2009, 15:1386-1393.
31. Haas R., Mohle R., Fruhauf S., et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994, 83:3787-3794.
32. Goncalves T.L., Benvegnu D.M., Bonfanti G. Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation. Oxid Med Cell Longev 2009, 2:82-87.
33. Menendez P., Caballero M.D., Prosper F., et al. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. Transfusion 2002, 42:1159-1172.
34. Kemp K., Morse R., Sanders K., et al. Alklating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells. Ann Hematol 2011, 90:777-789.
35. Xiao Y., Jiang Z.J., Pang Y., et al. Efficacy and safety of mesenchymal stem cell treatment from related donors for patients with refractory aplastic anemia. Cytotherapy 2013, 15:760-766.
36. Francese R., Fiorina P. Immunological and regenerative properties of cord blood stem cells. Clin Immunol 2010, 136:309-322.
37. Gluckman E., Rocha V. Cord blood transplantation: state of the art. Haematologica 2009, 94:451-454.
38. Gluckman E., Broxmever H.A., Auerbach A.D., et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical cord blood from an HLA-identical sibling. NEngl J Med 1989, 321:1174-1178.
39. Li Y., Sheng Z., Niu S., et al. Rapid and complete reconstitution of autologous haemopoiesis after cord blood infusion in treatment-naive patients with severe aplastic anemia receiving high-dose cyclophosphamide/ATG therapy. Eur J Haematol 2013, 90:45-50.
40. Takahashi S., Ooi J., Tomonari A., et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007, 109:1322-1330.
41. Zhou F., Ge L., Yu Z., et al. Clinical observations on intensive immunosuppressive therapy combined with umbilical cord blood support for the treatment of severe aplastic anemia [letter]. JHematol Oncol 2011, 4:27.
42. Robinson S.N., Simmons P.J., Yang H., et al. Mesenchymal stem cells in exvivo cord blood expansion. Best Pract Res Clin Haematol 2011, 24:83-92.
43. Liu H.L., Sun Z.M., Geng L.Q., et al. Unrelated cord blood transplantation for newly diagnosed patients with severe acquired anemia using a reduced-intensity conditioning: high graft rejection, but good survival. Bone Marrow Transplant 2012, 47:1186-1190.
44. Ning H., Yang F., Jiang M., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008, 22:593-599.
45. Sun H.Y., Li Z.Y., Xu K.L., et al. The clinical study of hematopoietic stem cell transplantation for hematological malignancies. Leuk Lymphoma 2006, 15:121-123.
46. Laudi N., Arora M., Burns L.J., et al. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005, 11:129-135.